Member Login

Untitled Document
Untitled Document

Research Area 1: Valve Replacement Repair

Cellular cardiomyoplasty (or cardiac cell therapy) appeared as an innovative and experimental therapy in 1992. The main goal of this strategy is to protect, repair and regenerate the injured heart with cells and, therefore, improve cardiac function. During last years, numerous clinical trials and animal studies have tested and improved the therapeutic potential of a great diversity of cells. Clinical studies of administration of isolated cells have revealed that homing and long-term engraftment, survival, growth and differentiation of transplanted cells in the infarct and peri-infarct areas are minimal, independently of the administration route, cell type and dose. Cardiac tissue engineering or tissue cardiomyoplasty, deals with the limitations of cellular cardiomyoplasty and involves three main combined strategies: the use of specific cell types, the application of defined scaffolds and the addition of signalling molecules or specific environments that can stimulate cells in a beneficial way.

Research Area 2: Myocardioplasty & Angioplasty

Valvular heart disease represents a common disorder that causes significant morbidity and mortality rates worldwide. Current surgical approaches include the replacement of the diseased valve with a mechanical or a bioprosthetic valve. Nevertheless, these valve replacements have severe drawbacks, such as the necessity for chronic anti-coagulation therapy with the mechanical valves, and the limited durability of the bioproshetic valves. Tissue engineered heart valves (TEHV) have emerged as a promising solution for heart valve replacement.

Untitled Document


TECAS-ITN End-of-Network Conference

 Padua, November 28-30, 2016

The TECAS-ITN European Doctoral Academy in Regenerative Engineering, is organising the End-of-Network Conference in Padua, Italy.

read more